1. Simvastatin restores pulmonary endothelial function in the setting of pulmonary over-circulation.
- Author
-
Boehme, Jason, Sun, Xutong, Lu, Qing, Barton, Jubilee, Wu, Xiaomin, Gong, Wenhui, Datar, Sanjeev, Wang, Ting, Fineman, Jeffrey, Black, Stephen, and Raff, Gary
- Subjects
Akt1 ,CTMP ,Congenital heart disease ,Endothelial dysfunction ,Endothelial nitric oxide synthase ,Nitric oxide ,Pulmonary hypertension ,Pulmonary vascular disease ,Humans ,Child ,Animals ,Sheep ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Simvastatin ,Endothelial Cells ,Nitric Oxide Synthase Type III ,Endothelium ,Vascular Diseases ,Nitric Oxide ,Endothelium ,Vascular - Abstract
Statin therapy is a cornerstone in the treatment of systemic vascular diseases. However, statins have failed to translate as therapeutics for pulmonary vascular disease. Early pulmonary vascular disease in the setting of congenital heart disease (CHD) is characterized by endothelial dysfunction, which precedes the more advanced stages of vascular remodeling. These features make CHD an ideal cohort in which to re-evaluate the potential pulmonary vascular benefits of statins, with a focus on endothelial biology. However, it is critical that the full gamut of the pleiotropic effects of statins in the endothelium are uncovered. The purpose of this investigation was to evaluate the therapeutic potential of simvastatin for children with CHD and pulmonary over-circulation, and examine mechanisms of simvastatin action on the endothelium. Our data demonstrate that daily simvastatin treatment preserves endothelial function in our shunt lamb model of pulmonary over-circulation. Further, using pulmonary arterial endothelial cells (PAECs) isolated from Shunt and control lambs, we identified a new mechanism of statin action mediated by increased expression of the endogenous Akt1 inhibitor, C-terminal modifying protein (CTMP). Increases in CTMP were able to decrease the Akt1-mediated mitochondrial redistribution of endothelial nitric oxide synthase (eNOS) which correlated with increased enzymatic coupling, identified by increases in NO generation and decreases in NOS-derived superoxide. Together our data identify a new mechanism by which simvastatin enhances NO signaling in the pulmonary endothelium and identify CTMP as a potential therapeutic target to prevent the endothelial dysfunction that occurs in children born with CHD resulting in pulmonary over-circulation.
- Published
- 2024